CSF2 and neoplasm: In vivo targeting of CD40+ APCs with a vaccine consisting on the A20 murine B cell lymphoma Id chemically conjugated to an anti-CD40 antibody induced more efficient tumor protection than a classic vaccination with Id-KLH plus GM-CSF.